Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

suicide prevention drug

- PMLiVE

J&J’s Rybrevant combination approved by FDA to treat EGFR-mutated NSCLC

Alterations in EGFR are among the most common driver mutations in lung cancer patients

- PMLiVE

AstraZeneca’s Fasenra receives FDA approval to treat rare inflammatory disease EGPA

Eosinophilic granulomatosis with polyangiitis affects approximately 15,000 people in the US

- PMLiVE

Merck’s Keytruda approved by FDA as first-line malignant pleural mesothelioma treatment

More than 30,000 new cases of mesothelioma were diagnosed globally in 2022

- PMLiVE

Novartis’ Kisqali combination granted FDA approval for early breast cancer patients

The drug is already approved for certain cases of advanced or metastatic breast cancer

- PMLiVE

Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS

The subcutaneous formulation has the same twice-yearly dosing schedule as the previously approved intravenous infusion

- PMLiVE

Eli Lilly announces FDA approval for Ebglyss in moderate-to-severe atopic dermatitis

The inflammatory skin condition occurs in 7.3% of adults in the US

- PMLiVE

Roche’s injectable PD-L1 inhibitor granted FDA approval for multiple cancer types

Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes

- PMLiVE

Johnson & Johnson’s IL-23 inhibitor Tremfya granted FDA approval for ulcerative colitis

The inflammatory bowel disease is estimated to affect more than one million people in the US

- PMLiVE

FDA grants full approval to Travere’s Filspari for rare kidney disease IgA nephropathy

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression

- PMLiVE

Novavax’s JN.1-adapted COVID-19 vaccine granted FDA emergency use authorisation

JN.1 only accounts for 0.2% of cases across the country but is the ‘parent strain’ of currently circulating variants

- PMLiVE

FDA approves updated COVID-19 vaccines to better protect against current variants

Adapted vaccines from Pfizer/BioNTech and Moderna have been authorised for individuals aged six months and older

- PMLiVE

Incyte and Syndax’s Niktimvo granted FDA approval in chronic graft versus host disease

Approximately 42% of patients receiving an allogeneic stem cell transplant will develop the condition

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links